One of the most talked-about stocks this week is Regeneron Pharmaceuticals Inc (NASDAQ: REGN) due to its COVID treatment. Biotech giant Regeneron claims that its antibody mix reduces the chance of COVID-19 infective. It has been claimed for nearly 82% over eight months. The trial resulted in zero deaths.
Personally, I have seen the treatment save the lives of over a dozen friends and family in Florida that took it. The consensus was that they felt better within 24 hours and no one went to the hospital. All have recovered without any long-term effect.
So it was no surprise when the results of the trial came out. The question you might be asking is, “is Regeneron stock a buy?”
The short answer is that I believe Regeneron is a buy for long-term investors that are looking for growth and understand the risks. The treatment appears to be very effective at a time when we are seeing vaccines greatly diminish their protection over time. However, there are now pills from Merck and Pfizer that are showing promise.
If you are looking at the chart for REGN, you will see stock price does fluctuate a lot, but the trend is bullish. It has dipped and touched the 200MA a few times, but this is not a bad thing. According to the pivot points, we could see a move up soon.
Table of Contents
Regeneron Trial Info
Monday’s announcement by the company included the results of clinical trials conducted in collaboration with the National Institute of Allergy and Infectious Diseases.
Two monoclonal antibodies are mixed in the REGEN-COV Antibody Cocktail. Regeneron claimed that the antibodies are non-competitive to the virus’s spike protein, specifically the “receptor binding area”, and protect against mutant viruses.
“With infections still occurring despite widespread vaccination, the immunocompromised face an ongoing risk of encountering the virus during their daily lives,” Dr. George Yancopoulos, president, said. “We intend to rapidly share these additional data with regulatory authorities to help those in most need of protection from COVID-19.”
The trial began in early 2021. Participants were allowed to become vaccinated once the primary efficacy period, which was 1 month, was over. The remaining months of the trial saw vaccination rates “balanced,” with 35% receiving vaccines from both the REGENCOV and placebo groups.
Regeneron Hedge Fund Activity
Large money managers and hedge funds tend to invest with a long-term view. They don’t need to be concerned about short-term slips and lumps. It could be different this time. Coronavirus caused a collapse in the high levels of correlation among large industries and asset classes. Now we are in a stock collectors’ market, where fundamentals have a greater impact on stock price than the overall direction. We see large and sudden changes in hedge fund positions depending on news flow. To determine whether there have been significant changes in hedge funds’ views towards Regeneron Pharmaceuticals Inc (NASDAQ : REGN), we examine the hedge fund sentiment.
Investors in Regeneron, should be aware that there has been an increase in activity from some of the largest hedge funds around. At the end of June, REGN stock was included in the portfolio 48 hedge funds. This statistic has a peak time of 49. It was not one of the top 30 most popular stocks by hedge funds according to our calculations.
Investors have many options when it comes to grading stocks in the financial world. Insider trading and hedge fund indicators are two of the most popular radar tools. Our research has shown that the best fund managers are more likely to outperform the wider indexes.
News & Analysis: Regeneron Pharmaceuticals Inc.
The stock Regeneron Pharmaceuticals is reportedly taking steps to test out the drug coronavirus. Cancer medication Libtayo might be slated by the federal agency for April 4th approval. Biopharma Group’s news may mean more for the medical industry than anybody fully believes. Both these companies are releasing annual revenue in the next month and some may see a decrease in their value. Combine rewards and risk-assigned products at this proven drug manufacturer. They can be surprising. The new FODC regulations on JAK inhibitors have caused both parties to lose their hopes.
Regeneron Pharmaceuticals Inc.
The company accelerates the traditional drug-development processes through proprietary VelociSuite technologies like VelocImmune. JAPAN DAKAN ARCALYST – ASCIAN SPORTING AND RELIGION PHY. The company was formally founded on January 8, 1988 by Alferd G. Gilman, Leonard S. Schleifer and Eric M. Shooter and has a factory at Tarrytown NY. The company is a biotechnology company specializing in the identification, invention, development, production and commercialization of medicines.